NCT02436447View on ClinicalTrials.gov

A Phase 1 Study Investigating the Safety and Pharmacokinetics of Repeat-dose Intravenous Infusion of MTP-131 in Subjects With Impaired Renal Function

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

July 31, 2015

Study Completion Date

October 31, 2015

Conditions
Normal and Impaired Renal Function
Interventions
DRUG

MTP-131

MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with normal renal function.

DRUG

MTP-131

MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with mild renal impairment.

DRUG

MTP-131

MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with moderate renal impairment

DRUG

MTP-131

MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with severe renal impairment

Trial Locations (1)

Unknown

Maimi

All Listed Sponsors
lead

Stealth BioTherapeutics Inc.

INDUSTRY

NCT02436447 - A Phase 1 Study Investigating the Safety and Pharmacokinetics of Repeat-dose Intravenous Infusion of MTP-131 in Subjects With Impaired Renal Function | Biotech Hunter | Biotech Hunter